OS Therapies Inc. Files S-1/A for IPO

TL;DR

OS Therapies Inc. filed an S-1/A for its IPO. Get ready for some new pharma stock.

AI Summary

OS Therapies Inc. filed an S-1/A amendment on November 27, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Grasonville, Maryland, and operates in the pharmaceutical preparations sector. The filing details its registration statement under the Securities Act of 1933.

Why It Matters

This S-1/A filing indicates OS Therapies Inc. is moving forward with its plan to become a publicly traded company, which could provide it with capital for growth and development.

Risk Assessment

Risk Level: medium — As a company undergoing an IPO, the inherent risks of a new public offering and the pharmaceutical industry apply.

Key Numbers

• 2834 — SIC Code (Pharmaceutical Preparations industry)

Key Players & Entities

• OS Therapies Inc. (company) — Registrant
• November 27, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Grasonville, Maryland (location) — Business address
• Paul A. Romness (person) — President and Chief Executive Officer
• 333-283171 (registration_number) — SEC file number

FAQ

Key Financial Figures

• $0.001 — f our shares of common stock, par value $0.001 per share, in an offering amount of up
• $15,000,000 — r share, in an offering amount of up to $15,000,000 (the "ELOC Shares"), which would repres
• $2.68 — e NYSE American on November 11, 2024 of $2.68 per share, that have been or may be iss
• $2 — declared effective by the SEC is below $2.715, the closing price of our common st
• $2.00 — of our shares on the NYSE American was $2.00 per share. Given the relative lack of
• $6,400,000 — blic offering on July 31, 2024, raising $6,400,000 in gross offering proceeds. The Equity

Filing Documents

• ea0220575-02.htm (S-1/A) — 5784KB
• ea022057502ex5-1_ostherapi.htm (EX-5.1) — 10KB
• ea022057502ex23-1_ostherapi.htm (EX-23.1) — 5KB
• ex5-1_001.jpg (GRAPHIC) — 38KB
• ex5-1_002.jpg (GRAPHIC) — 22KB
• ex23-1_001.jpg (GRAPHIC) — 19KB
• ex23-1_002.jpg (GRAPHIC) — 113KB
• tos_logo.jpg (GRAPHIC) — 83KB
• tflowchart_001.jpg (GRAPHIC) — 311KB
• 0001213900-24-103456.txt ( ) — 16431KB
• ostx-20240930.xsd (EX-101.SCH) — 71KB
• ostx-20240930_cal.xml (EX-101.CAL) — 32KB
• ostx-20240930_def.xml (EX-101.DEF) — 323KB
• ostx-20240930_lab.xml (EX-101.LAB) — 494KB
• ostx-20240930_pre.xml (EX-101.PRE) — 334KB
• ea0220575-02_htm.xml (XML) — 2850KB

RISK FACTORS

RISK FACTORS 11 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 47 THE EQUITY LINE OF CREDIT 48

USE OF PROCEEDS

USE OF PROCEEDS 52 DIVIDEND POLICY 52

MANAGEMENT'S DISCUSSION AND ANALYSIS OFFINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OFFINANCIAL CONDITION AND RESULTS OF OPERATIONS 54

BUSINESS

BUSINESS 63 MANAGEMENT 81

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 88

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 92 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 93

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 95 SELLING STOCKHOLDER 100 PLAN OF DISTRIBUTION 101 LEGAL MATTERS 103 EXPERTS 103 WHERE YOU CAN FIND MORE INFORMATION 103 INDEX TO FINANCIAL STATEMENTS F -1 i Table of Contents ABOUT THIS PROSPECTUS Neither we nor the Investor authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We are not, and the Investor is not, making an offer of these securities in any jurisdiction where such offer is not permitted. The industry and market data and certain other statistical information used throughout this prospectus are from our own research, surveys or studies conducted by third parties and industry or general publications. Industry publications and third -party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe that these sources are reliable; however, we have not independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third -party information presented in thi

View Full Filing

View this S-1/A filing on SEC EDGAR